HK1212383A1 - Pr13.5 promoter for robust t-cell and antibody responses - Google Patents
Pr13.5 promoter for robust t-cell and antibody responses Download PDFInfo
- Publication number
- HK1212383A1 HK1212383A1 HK16100267.8A HK16100267A HK1212383A1 HK 1212383 A1 HK1212383 A1 HK 1212383A1 HK 16100267 A HK16100267 A HK 16100267A HK 1212383 A1 HK1212383 A1 HK 1212383A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cell
- antibody responses
- promoter
- robust
- mva
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719429P | 2012-10-28 | 2012-10-28 | |
| US61/719,429 | 2012-10-28 | ||
| PCT/EP2013/003239 WO2014063832A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK42021034755.5A Division HK40044708A (en) | 2012-10-28 | 2016-01-12 | Pr13.5 promoter for robust t-cell and antibody responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK42021034755.5A Addition HK40044708A (en) | 2012-10-28 | 2016-01-12 | Pr13.5 promoter for robust t-cell and antibody responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1212383A1 true HK1212383A1 (en) | 2016-06-10 |
Family
ID=49513897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100267.8A HK1212383A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9828414B2 (enExample) |
| EP (2) | EP2912183B1 (enExample) |
| JP (2) | JP6505016B2 (enExample) |
| KR (2) | KR102135818B1 (enExample) |
| CN (1) | CN104755622B (enExample) |
| AU (1) | AU2013337018B2 (enExample) |
| BR (1) | BR112015009320A2 (enExample) |
| CA (1) | CA2887623C (enExample) |
| CY (1) | CY1123181T1 (enExample) |
| DK (1) | DK2912183T3 (enExample) |
| EA (2) | EA201990114A1 (enExample) |
| ES (1) | ES2800623T3 (enExample) |
| HK (1) | HK1212383A1 (enExample) |
| HU (1) | HUE049706T2 (enExample) |
| IL (1) | IL238130B (enExample) |
| IN (1) | IN2015DN03326A (enExample) |
| LT (1) | LT2912183T (enExample) |
| MX (2) | MX380483B (enExample) |
| MY (2) | MY171687A (enExample) |
| NZ (1) | NZ706637A (enExample) |
| PT (1) | PT2912183T (enExample) |
| SG (2) | SG11201503200PA (enExample) |
| SI (1) | SI2912183T1 (enExample) |
| UA (1) | UA118340C2 (enExample) |
| WO (1) | WO2014063832A1 (enExample) |
| ZA (1) | ZA201502892B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015DN03326A (enExample) * | 2012-10-28 | 2015-10-09 | Bavarian Nordic As | |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| HUE059343T2 (hu) | 2016-01-29 | 2022-11-28 | Bavarian Nordic As | Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag |
| WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| US11052139B2 (en) | 2016-09-28 | 2021-07-06 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| BR112020003669A2 (pt) | 2017-08-24 | 2020-09-01 | Bavarian Nordic A/S | terapia de combinação para tratamento do câncer com administração intravenosa de um mva recombinante e de um anticorpo |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| GB201807932D0 (en) * | 2018-05-16 | 2018-06-27 | Redchenko Irina | Compositions and methods for inducing an immune response |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CN110904127B (zh) | 2018-09-18 | 2024-09-20 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| JP7625518B2 (ja) | 2018-11-20 | 2025-02-03 | バヴァリアン・ノルディック・アクティーゼルスカブ | ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法 |
| EP4061406A1 (en) | 2019-11-20 | 2022-09-28 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
| IL298834A (en) | 2020-06-10 | 2023-02-01 | Bavarian Nordic As | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| IL311078A (en) | 2021-09-03 | 2024-04-01 | Bavarian Nordic As | Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva) |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| CN119630419A (zh) | 2022-06-29 | 2025-03-14 | 巴法里安诺迪克有限公司 | 重组修饰的saRNA(VRP)和痘苗病毒安卡拉(MVA)初免-加强方案 |
| TW202413636A (zh) | 2022-08-18 | 2024-04-01 | 法商傳斯堅公司 | 嵌合痘病毒 |
| WO2024149832A1 (en) | 2023-01-12 | 2024-07-18 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2025238220A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles |
| WO2025238218A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding antigen-displaying protein nanoparticles |
| WO2025238221A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding multi-antigen-displaying protein nanoparticles |
| WO2025238219A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| AU3163902A (en) | 2000-11-23 | 2002-06-03 | Bavarian Nordic Res Inst As | Modified vaccinia ankara virus variant |
| BRPI0512421B8 (pt) * | 2004-06-25 | 2022-06-28 | Merial Ltd | Recombinantes de avipox expressando genes do vírus da doença febre aftosa |
| JP2008301792A (ja) | 2007-06-11 | 2008-12-18 | National Univ Corp Shizuoka Univ | 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法 |
| AU2009319336B2 (en) | 2008-11-27 | 2015-03-26 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| IN2015DN03326A (enExample) * | 2012-10-28 | 2015-10-09 | Bavarian Nordic As |
-
2013
- 2013-10-28 IN IN3326DEN2015 patent/IN2015DN03326A/en unknown
- 2013-10-28 EA EA201990114A patent/EA201990114A1/ru unknown
- 2013-10-28 SG SG11201503200PA patent/SG11201503200PA/en unknown
- 2013-10-28 HK HK16100267.8A patent/HK1212383A1/xx unknown
- 2013-10-28 KR KR1020157009206A patent/KR102135818B1/ko active Active
- 2013-10-28 WO PCT/EP2013/003239 patent/WO2014063832A1/en not_active Ceased
- 2013-10-28 PT PT137838520T patent/PT2912183T/pt unknown
- 2013-10-28 MY MYPI2015701223A patent/MY171687A/en unknown
- 2013-10-28 US US14/437,939 patent/US9828414B2/en active Active
- 2013-10-28 MY MYPI2018001787A patent/MY194609A/en unknown
- 2013-10-28 EP EP13783852.0A patent/EP2912183B1/en active Active
- 2013-10-28 KR KR1020207020263A patent/KR20200087880A/ko not_active Ceased
- 2013-10-28 EP EP20172647.8A patent/EP3778904A1/en active Pending
- 2013-10-28 LT LTEP13783852.0T patent/LT2912183T/lt unknown
- 2013-10-28 AU AU2013337018A patent/AU2013337018B2/en active Active
- 2013-10-28 MX MX2015005264A patent/MX380483B/es unknown
- 2013-10-28 DK DK13783852.0T patent/DK2912183T3/da active
- 2013-10-28 NZ NZ706637A patent/NZ706637A/en unknown
- 2013-10-28 HU HUE13783852A patent/HUE049706T2/hu unknown
- 2013-10-28 ES ES13783852T patent/ES2800623T3/es active Active
- 2013-10-28 EA EA201590831A patent/EA032498B1/ru not_active IP Right Cessation
- 2013-10-28 CN CN201380054013.0A patent/CN104755622B/zh active Active
- 2013-10-28 SG SG10201704657WA patent/SG10201704657WA/en unknown
- 2013-10-28 BR BR112015009320A patent/BR112015009320A2/pt not_active Application Discontinuation
- 2013-10-28 JP JP2015538330A patent/JP6505016B2/ja active Active
- 2013-10-28 SI SI201331731T patent/SI2912183T1/sl unknown
- 2013-10-28 CA CA2887623A patent/CA2887623C/en active Active
- 2013-10-28 UA UAA201505223A patent/UA118340C2/uk unknown
-
2015
- 2015-04-02 IL IL238130A patent/IL238130B/en active IP Right Grant
- 2015-04-24 MX MX2021001638A patent/MX2021001638A/es unknown
- 2015-04-28 ZA ZA2015/02892A patent/ZA201502892B/en unknown
-
2017
- 2017-11-22 US US15/821,035 patent/US11028130B2/en active Active
-
2019
- 2019-03-22 JP JP2019054129A patent/JP6818797B2/ja active Active
-
2020
- 2020-07-08 CY CY20201100630T patent/CY1123181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212383A1 (en) | Pr13.5 promoter for robust t-cell and antibody responses | |
| NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
| JP2015533841A5 (enExample) | ||
| CA2856895C (en) | Anti-pd-l1 antibodies and uses thereof | |
| WO2014005683A8 (en) | Dna vaccine for use in pancreatic cancer patients | |
| WO2011032161A8 (en) | Vaccines directed to langerhans cells | |
| WO2012106231A3 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses | |
| MY156997A (en) | Replication deficient recombinant viruses expressing antigents regulated by transcriptional control elements comprising multiple elements | |
| WO2011110953A3 (en) | Polyepitope constructs and methods for their preparation and use | |
| EA201590304A1 (ru) | Вакцина рекомбинантного модифицированного вируса осповакцины анкара респираторно-синцитиального вируса | |
| WO2017066706A8 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| WO2014097050A9 (en) | Strain of bifidobacterium animalis ssp. animalis | |
| WO2012018907A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| AU2013358947A8 (en) | WT1 vaccine | |
| WO2012047267A3 (en) | Polyvalent immunogen | |
| IN2015DN02335A (enExample) | ||
| NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| WO2013138259A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| MX2010007876A (es) | Vectores virales recombinantes y composicion de vacuna para leishmaniasis. | |
| CA2886450C (en) | Cooperia vaccine | |
| WO2014015287A3 (en) | Influenza vaccine consisting of a mva which expresses influenza antigens fused to vaccinia secretory signal sequences | |
| MX374919B (es) | ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae. | |
| WO2008118936A3 (en) | Method of elicting immune response with a modified mva viral hiv-1 vector | |
| WO2012178078A3 (en) | Use of yscf, truncated yscf and yscf homologs as adjuvants |